Oakland, California
United States
26
2025-07-31
The entities that hold a legal rights for patent applications filed by inventor Lamb Peter:
Peter Lamb from Oakland, US has applied for patents for these inventions. The list has both pending applications and granted patents:
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#2 | 2025-03-13Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-Nā²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#3 | 2024-08-22Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#4 | 2023-09-28COMBINATIONS FOR THE TREATMENT OF CANCER
#5 | 2023-06-01Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#6 | 2022-08-18Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
#7 | 2022-02-03Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#8 | 2021-10-28Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
#9 | 2021-06-03Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-Nā²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#10 | 2021-05-13Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- Nā²-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
#11 | 2021-01-28Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-Nā²-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
#12 | 2020-06-18Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
#13 | 2018-02-08Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#14 | 2018-01-04Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#15 | 2017-09-28Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
#16 | 2017-08-10Drug combinations to treat multiple myeloma
#17 | 2015-02-26Malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-Nā²(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
#18 | 2014-04-10Methods of Using PI3K and MEK Modulators
#19 | 2012-11-29Method of using PI3K and MEK modulators
#20 | 2012-02-09(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
#21 | 2011-12-08Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents
#22 | 2011-05-26Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
#23 | 2010-08-19Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
#24 | 2010-03-25Methods of Using PI3K and MEK Modulators
#25 | 2008-07-10Methods of using MEK inhibitors
#26 | 2006-09-21Protein kinase modulators and methods of use
720139 ā